The Manufacturers Life Insurance Company boosted its position in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 8.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 104,447 shares of the biotechnology company’s stock after purchasing an additional 7,946 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.07% of ZIOPHARM Oncology worth $649,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in ZIOPHARM Oncology by 7.6% during the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after purchasing an additional 553,933 shares in the last quarter. State Street Corp boosted its position in ZIOPHARM Oncology by 12.8% during the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after purchasing an additional 517,057 shares in the last quarter. Northern Trust Corp boosted its position in ZIOPHARM Oncology by 10.1% during the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after purchasing an additional 149,067 shares in the last quarter. Geode Capital Management LLC boosted its position in ZIOPHARM Oncology by 3.9% during the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock worth $6,444,000 after purchasing an additional 38,173 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in ZIOPHARM Oncology by 2.2% during the second quarter. Bank of New York Mellon Corp now owns 611,533 shares of the biotechnology company’s stock worth $3,804,000 after purchasing an additional 13,127 shares in the last quarter. Institutional investors own 41.90% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/ziopharm-oncology-inc-ziop-shares-bought-by-the-manufacturers-life-insurance-company/1715261.html.

Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) opened at $4.57 on Monday. ZIOPHARM Oncology Inc has a 12-month low of $4.03 and a 12-month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. research analysts forecast that ZIOPHARM Oncology Inc will post -0.54 EPS for the current fiscal year.

ZIOP has been the topic of several recent research reports. Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Friday, November 10th. HC Wainwright restated a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a research report on Tuesday, November 7th. BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, ValuEngine upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. ZIOPHARM Oncology presently has a consensus rating of “Hold” and a consensus target price of $12.58.

In related news, CEO Laurence James Neil Cooper acquired 6,440 shares of ZIOPHARM Oncology stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the completion of the transaction, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 10.40% of the stock is owned by corporate insiders.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.